Invesco Biotechnology & Genome ETF
PBE
74 hedge funds and large institutions have $53.2M invested in Invesco Biotechnology & Genome ETF in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 22 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
7% more funds holding
Funds holding: 69 → 74 (+5)
2% more capital invested
Capital invested by funds: $52.3M → $53.2M (+$896K)
0.07% less ownership
Funds ownership: 22.16% → 22.09% (-0.07%)
41% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PSF
Pacific Sun Financial
Los Angeles,
California
|
+$662K |
| 2 |
Jane Street
New York
|
+$390K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$311K |
| 4 |
Morgan Stanley
New York
|
+$309K |
| 5 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$212K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$1.52M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$345K |
| 3 |
TAM
Trillium Asset Management
Boston,
Massachusetts
|
-$320K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$237K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$233K |
PBE Hedge Fund Activity: Q1 2018 in Review
74 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q1 2018, worth a combined $53.2M — up 1.7% from $52.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PBE positions and 4 closed out — a net gain of 5 holders — while 13 added to existing stakes and 22 trimmed.
The largest buyer was Pacific Sun Financial, opening a new position worth an estimated $662K. The largest seller was Virtu Financial, cutting an estimated $1.52M.
- 74 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q1 2018, up from 69 in Q4 2017.
- Funds reported $53.2M of Invesco Biotechnology & Genome ETF stock for Q1 2018, up 1.7% quarter-over-quarter.
- 9 funds opened new Invesco Biotechnology & Genome ETF positions in Q1 2018 and 4 closed out, a net change of +5 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q1 2018 was Pacific Sun Financial, an estimated $662K added.
- The largest Invesco Biotechnology & Genome ETF seller in Q1 2018 was Virtu Financial, an estimated $1.52M sold.
Based on aggregated 13F filings for Q1 2018.